NCT07645326
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatmentGeorgetown UniversityInvestigator-initiated
~108 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Androgen Deprivation Therapy (ADT)Androgen Receptor Pathway Inhibitor (ARPI)Prostate RadiationDocetaxel
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Radiological progression-free survival (rPFS)
Measured over 36 months
Conditions
Where it's being run
1 sites across 1 statesDistrict of Columbia1
Study leadership
- Paul D Leger, MD · PRINCIPAL_INVESTIGATOR · Georgetown University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Radiological progression-free survival (rPFS)36 months
rPFS is defined as the time from the first dose of systemic therapy for mCSPC to the first documented radiological progression in soft tissue or bone, based on CT, MRI, or NM bone scan, using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for soft-tissue metastases and Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases, or death from any cause.